SARS-CoV-2 IgG Antibody Testing is Now Available at Wisconsin Diagnostic Laboratories (WDL)

Intended use:
Antibody testing (also called serology testing) is intended to help identify individuals who have developed antibodies against SARS-CoV-2. A positive result is evidence of prior infection with this virus. Infection may be symptomatic or asymptomatic.

Test Performance:
Testing performed at WDL has shown high sensitivity (~99% by day 14 after contracting the virus) and specificity (99.2 - 99.8%) for SARS-CoV-2. This test qualitatively detects IgG antibody.

- Positive antibody results are seen in most immunocompetent individuals by day 14 after contracting the virus.
- Prevalence plays an important role in test results. The risk of false-positive results is greater when disease prevalence is low. The higher the prevalence, the less chance of a false-positive result. Always consider local prevalence information, as it becomes available, when interpreting results.

Acute Infection and Immunity:
- Do not use antibody testing to diagnose acute infection. Studies performed at WDL have demonstrated less than 50% sensitivity when used for diagnosis of acute COVID-19 disease.
- It is currently unknown if the presence of antibodies indicates immunity to SARS-CoV-2.

Test Details:

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Mnemonic</th>
<th>Test Code</th>
<th>Epic Code</th>
<th>CPT Code</th>
<th>Collect</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 IgG Antibody</td>
<td>COVID IGG</td>
<td>4500870</td>
<td>LAB125</td>
<td>86769</td>
<td>Gold-top SST (Preferred) or Light Green-top PST or Lavender-top EDTA</td>
</tr>
</tbody>
</table>

For Technical Questions or Additional Information, Please Contact:
- Ian Gunsolus, PhD, Co-Director of Clinical Chemistry and Toxicology, 414.805.6972, igunsolus@mcw.edu
- Laura Smy, PhD, MLS, Co-Director of Clinical Chemistry and Toxicology, 414.805-6975, lsmy@mcw.edu